Analysts Set Novo Nordisk A/S (NYSE:NVO) Target Price at $159.65
Novo Nordisk A/S (NYSE:NVO) has earned an average rating of “Hold” from the eighteen analysts that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $159.65.
Several brokerages have weighed in on NVO. Bank of America increased their price target on shares of Novo Nordisk A/S from $355.00 to $400.00 and gave the company a “neutral” rating in a research report on Friday, September 13th. Zacks Investment Research raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price target for the company in a research report on Monday, July 15th. Pareto Securities raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, August 5th. Jefferies Financial Group cut shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research report on Friday, August 30th. Finally, Deutsche Bank cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price target for the company. in a research report on Thursday, June 20th.
Institutional investors and hedge funds have recently made changes to their positions in the business. Advisors Preferred LLC purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth about $26,000. TCG Advisors LP purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $27,000. Valeo Financial Advisors LLC lifted its position in shares of Novo Nordisk A/S by 510.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock worth $32,000 after purchasing an additional 526 shares during the period. Bremer Bank National Association purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $41,000. Finally, Wealthcare Advisory Partners LLC lifted its position in shares of Novo Nordisk A/S by 75.6% in the 2nd quarter. Wealthcare Advisory Partners LLC now owns 864 shares of the company’s stock worth $44,000 after purchasing an additional 372 shares during the period. 7.34% of the stock is owned by institutional investors and hedge funds.
Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Friday, August 9th. The company reported $0.61 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.61. Novo Nordisk A/S had a net margin of 32.16% and a return on equity of 75.16%. The company had revenue of $4.52 billion during the quarter, compared to analysts’ expectations of $4.41 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 2.43 EPS for the current year.
The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, August 27th. Shareholders of record on Monday, August 19th were given a dividend of $0.318 per share. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s payout ratio is currently 25.40%.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Featured Article: Marijuana Stocks
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.